文献速递艾滋病与性传播感染

HIV C亚型DNA与MF59佐剂包膜蛋白疫苗的1期人体试验

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
PubMed 文献 · Clin Infect Dis · 2021-01-01

所有接种安全耐受,DNA/蛋白共同接种提高V1/V2抗体应答率,Biojector给予DNA在初免/加强方案中显著提高CD4+ T细胞应答率。

要点

  • DNA/蛋白共同接种与V1/V2抗体应答率升高相关,该应答是降低HIV-1感染风险的已知相关因素。
  • 初免/加强和共同接种方案均安全,可根据所需细胞或体液免疫选择推进效力试验。

核心结论

  • DNA初免/蛋白加强和DNA/蛋白共同接种方案均安全,并可能根据所需细胞或体液应答推进效力试验。

研究设计与样本

  • 6组分别为:DNA初免/蛋白加强经针筒、DNA/蛋白共同接种经针筒、针筒安慰剂、DNA初免/蛋白加强经Biojector给DNA、DNA/蛋白共同接种经Biojector给DNA、Biojector安慰剂。

主要发现

  • 所有疫苗接种安全且耐受良好。
  • DNA/蛋白共同接种与HIV-1 V1/V2抗体应答率升高相关,该应答是降低HIV-1感染风险的已知相关因素。

临床怎么用

  • 若目标是增强体液免疫(V1/V2抗体),可考虑DNA/蛋白共同接种方案。
  • 若目标是增强细胞免疫(CD4+ T细胞),在初免/加强方案中可考虑用Biojector给予DNA。
  • 两种方案均安全,可根据免疫目标选择推进后续效力试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Pox-Protein Public-Private Partnership is performing a suite of trials to evaluate the bivalent subtype C envelope protein (TV1.C and 1086.C glycoprotein 120) vaccine in the context of different adjuvants and priming agents for human immunodeficiency virus (HIV) type 1 (HIV-1) prevention. METHODS: In the HIV Vaccine Trials Network 111 trial, we compared the safety and immunogenicity of DNA prime followed by DNA/protein boost with DNA/protein coadministration injected intramuscularly via either needle/syringe or a needle-free injection device (Biojector). One hundred thirty-two healthy, HIV-1-uninfected adults were enrolled from Zambia, South Africa, and Tanzania and were randomized to 1 of 6 arms: DNA prime, protein boost by needle/syringe; DNA and protein coadministration by needle/syringe; placebo by needle/syringe; DNA prime, protein boost with DNA given by Biojector; DNA and protein coadministration with DNA given by Biojector; and placebo by Biojector. RESULTS: All vaccinations were safe and well tolerated. DNA and protein coadministration was associated with increased HIV-1 V1/V2 antibody response rate, a known correlate of decreased HIV-1 infection risk. DNA administration by Biojector elicited significantly higher CD4+ T-cell response rates to HIV envelope protein than administration by needle/syringe in the prime/boost regimen (85.7% vs 55.6%; P = .02), but not in the coadministration regimen (43.3% vs 48.3%; P = .61). CONCLUSIONS: Both the prime/boost and coadministration regimens are safe and may be promising for advancement into efficacy trials depending on whether cellular or humoral responses are desired. CLINICAL TRIALS REGISTRATION: South African National Clinical Trials Registry (application 3947; Department of Health [DoH] no. DOH-27-0715-4917) and ClinicalTrials.gov (NCT02997969).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hosseinipour MC, Innes C, Naidoo S, et al. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clin Infect Dis. 2021. PMID: 31900486. doi:10.1093/cid/ciz1239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。